Keyphrases
Acute Myeloid Leukemia
100%
Myelodysplastic Syndrome
61%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
23%
FMS-like Tyrosine Kinase 3 (FLT3)
21%
Hematopoietic Stem Cells
21%
Azacitidine
18%
Overall Survival
17%
All-trans Retinoic Acid
15%
Complete Remission
15%
Peripheral Blood
14%
FLT3 Internal Tandem Duplication
12%
Lenalidomide
12%
Leukemia Patients
11%
Low-risk Myelodysplastic Syndromes
11%
Clonal Hematopoiesis
11%
Prognostic Impact
11%
Bone Marrow
10%
Leukemia
10%
Minimal Residual Disease
9%
Intensive Chemotherapy
9%
Multiple Myeloma
9%
Nucleophosmin 1 (NPM1)
9%
FLT3-ITD
9%
CD34+
8%
Phase II Trial
8%
Hypomethylating Agents
8%
Relapsed or Refractory Acute Myeloid Leukemia
8%
Hematopoiesis
8%
Secondary Acute Myeloid Leukemia (sAML)
8%
Gemtuzumab Ozogamicin
8%
Chemotherapy
7%
Newly Diagnosed
7%
CD34+ Cells
7%
Phase II Study
7%
High-risk Myelodysplastic Syndrome
7%
Hazard Ratio
7%
Placebo
7%
Austrian
7%
C-X-C Chemokine Receptor Type 4 (CXCR4)
7%
High Risk
7%
Older Patients
6%
High-dose Cytarabine
6%
International Prognostic Scoring System
6%
Decitabine
6%
Progenitor Cells
6%
Stromal Cells
6%
Hematological Malignancies
6%
Luspatercept
6%
Induction Therapy
6%
Cytarabine
6%
Medicine and Dentistry
Acute Myeloid Leukemia
70%
Myelodysplastic Syndrome
46%
Azacitidine
19%
Overall Survival
16%
Hematopoietic Cell
13%
Tretinoin
11%
Acute Myelogenous Leukemia
11%
Cell Transplantation
11%
Hematopoiesis
10%
Leukemia
10%
Cytarabine
9%
NPM1
8%
Hypomethylating Agent
8%
Diseases
7%
Minimal Residual Disease
7%
Arm
6%
Allogeneic Hematopoietic Stem Cell Transplantation
6%
Secondary Acute Myeloid Leukemia
6%
Placebo
6%
In Vitro
6%
Gemtuzumab Ozogamicin
6%
Luspatercept
6%
Anemia
6%
Midostaurin
5%
Sorafenib
5%
Event Free Survival
5%
Lenalidomide
5%
Hazard Ratio
5%
Allogeneic Stem Cell Transplantation
5%
Multiple Myeloma
5%
Cancer
5%
International Prognostic Scoring System
5%
Prognostic Factor
5%
Decitabine
5%
Neoplasm
5%
Drug Megadose
5%
